title: Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
authors.forename: David
authors.initials: D
authors.lastname: Gurwitz
authors.forename: William
authors.initials: W
authors.lastname: Newman
mesh_terms: D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use; D044466:Asian People / Q000706:statistics & numerical data; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000208:ethnology / Q000235:genetics* / Q000401:mortality; D017024:Chemotherapy, Adjuvant; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D003657:Decision Making; D018572:Disease-Free Survival; D020847:Estrogen Receptor Modulators / Q000493:pharmacokinetics / Q000627:therapeutic use; D005260:Female; D005838:Genotype; D006801:Humans; D008390:Markov Chains; D008875:Middle Aged; D009570:Nitriles / Q000493:pharmacokinetics / Q000627:therapeutic use; D010358:Patient Participation; D017698:Postmenopause; D013629:Tamoxifen / Q000493:pharmacokinetics / Q000627:therapeutic use; D014230:Triazoles / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D020847:Estrogen Receptor Modulators; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole; D019389:Cytochrome P-450 CYP2D6